Pozen Migraine Combo “Not Approvable”; Company Seeks Meeting With FDA

Naproxen/metoclopramide fixed-dose combo did not meet efficacy endpoints in second study, FDA letter says. Agency also questions potential risk of tardive dyskinesia and carcinogenicity in denying approval of MT-100.